Breaking News Instant updates and real-time market news.

IVPAF

Ivanhoe Mines

$0.00 /

+ (+0.00%)

10:31
01/06/21
01/06
10:31
01/06/21
10:31

Ivanhoe Mines price target raised to C$9 from C$8 at TD Securities

TD Securities analyst Greg Barnes raised the firm's price target on Ivanhoe Mines to C$9 from C$8 and keeps a Buy rating on the shares.

IVPAF Ivanhoe Mines
$0.00 /

+ (+0.00%)

09/24/20 Raymond James
Ivanhoe Mines price target raised to C$7.50 from C$7 at Raymond James
09/11/20 Raymond James
Ivanhoe Mines price target raised to C$7 from C$6 at Raymond James
09/11/20 BMO Capital
Ivanhoe Mines price target raised to C$10 from C$9 at BMO Capital
09/09/20 Canaccord
Ivanhoe Mines price target raised to C$7 from C$5.50 at Canaccord

TODAY'S FREE FLY STORIES

Hot Stocks
Air Canada to resume Boeing 737 MAX commercial operations on Feb. 1 » 13:11
01/18/21
01/18
13:11
01/18/21
13:11
ACDVF

Air Canada

$0.00 /

+ (+0.00%)

, BA

Boeing

$204.29 /

-5.6 (-2.67%)

Air Canada (ACDVF) said…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ACDVF Air Canada
$0.00 /

+ (+0.00%)

BA Boeing
$204.29 /

-5.6 (-2.67%)

ACDVF Air Canada
$0.00 /

+ (+0.00%)

01/11/21 Cowen
Air Canada upgraded to Outperform from Market Perform at Cowen
01/08/21 BofA
Air Canada upgraded to Buy from Neutral at BofA
01/05/21 RBC Capital
Air Canada price target lowered to C$27 from C$30 at RBC Capital
01/04/21 Scotiabank
Air Canada price target lowered to C$29 from C$30 at Scotiabank
BA Boeing
$204.29 /

-5.6 (-2.67%)

01/04/21
Fly Intel: Top five analyst downgrades
01/04/21 Baird
Boeing elevated to Fresh Pick at Baird
01/04/21 Bernstein
Bernstein downgrades Boeing to Underperform on worsening 787 outlook
01/04/21 Bernstein
Boeing downgraded to Underperform from Market Perform at Bernstein
BA Boeing
$204.29 /

-5.6 (-2.67%)

ACDVF Air Canada
$0.00 /

+ (+0.00%)

BA Boeing
$204.29 /

-5.6 (-2.67%)

BA Boeing
$204.29 /

-5.6 (-2.67%)

BA Boeing
$204.29 /

-5.6 (-2.67%)

Initiation
Tesco reinstated with a Buy at Goldman Sachs » 13:09
01/18/21
01/18
13:09
01/18/21
13:09
TSCDY

Tesco

$0.00 /

+ (+0.00%)

Goldman Sachs analyst Rob…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
TSCDY Tesco
$0.00 /

+ (+0.00%)

TSCDY Tesco
$0.00 /

+ (+0.00%)

01/04/21 Barclays
Tesco reinstated with an Overweight at Barclays
01/04/21 Barclays
Tesco reinstated with an Overweight at Barclays
12/17/20 Morgan Stanley
Tesco price target raised to 287 GBp from 276 GBp at Morgan Stanley
10/23/20 Kepler Cheuvreux
Tesco downgraded to Hold from Buy at Kepler Cheuvreux
Hot Stocks
Biohaven's troriluzole did not differentiate from placebo in Alzheimer's trial » 13:06
01/18/21
01/18
13:06
01/18/21
13:06
BHVN

Biohaven Pharmaceutical

$84.76 /

-7.065 (-7.69%)

Biohaven Pharmaceutical…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
BHVN Biohaven Pharmaceutical
$84.76 /

-7.065 (-7.69%)

BHVN Biohaven Pharmaceutical
$84.76 /

-7.065 (-7.69%)

12/29/20 Cantor Fitzgerald
Biohaven price target raised to $115 from $109 at Cantor Fitzgerald
12/23/20 Piper Sandler
Piper 'comfortable' owning Biohaven shares into Alzheimer's readout
12/15/20 H.C. Wainwright
Biohaven Pharmaceutical initiated with a Buy at H.C. Wainwright
12/07/20 SVB Leerink
Biohaven Pharmaceutical price target raised to $120 from $85 at SVB Leerink
BHVN Biohaven Pharmaceutical
$84.76 /

-7.065 (-7.69%)

  • 29
    Jan
Hot Stocks
Granite announces $20M contact by California Department of Transportation » 13:02
01/18/21
01/18
13:02
01/18/21
13:02
GVA

Granite

$33.21 /

-0.7 (-2.06%)

Granite announced that it…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
GVA Granite
$33.21 /

-0.7 (-2.06%)

GVA Granite
$33.21 /

-0.7 (-2.06%)

06/25/20 DA Davidson
Granite Construction price target lowered to $17 from $30 at DA Davidson
GVA Granite
$33.21 /

-0.7 (-2.06%)

Hot Stocks
Equinox announces positive drill results from Piaba Underground target » 13:00
01/18/21
01/18
13:00
01/18/21
13:00
EQX

Equinox Gold

$10.03 /

-0.455 (-4.34%)

Equinox Gold announced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
EQX Equinox Gold
$10.03 /

-0.455 (-4.34%)

EQX Equinox Gold
$10.03 /

-0.455 (-4.34%)

01/12/21 BMO Capital
Equinox Gold price target raised to C$22.50 from C$22 at BMO Capital
01/11/21 National Bank
Equinox Gold price target lowered to C$17 from C$18 at National Bank
01/11/21 Scotiabank
Equinox Gold price target lowered to C$18.25 from C$19.25 at Scotiabank
12/21/20 BMO Capital
Equinox Gold price target raised to C$22 from C$21.50 at BMO Capital
EQX Equinox Gold
$10.03 /

-0.455 (-4.34%)

Hot Stocks
AstraZeneca, Daiichi announce FDA approval of Enhertu for gastric cancer » 12:58
01/18/21
01/18
12:58
01/18/21
12:58
AZN

AstraZeneca

$51.35 /

+0.05 (+0.10%)

AstraZeneca and Daiichi…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
AZN AstraZeneca
$51.35 /

+0.05 (+0.10%)

AZN AstraZeneca
$51.35 /

+0.05 (+0.10%)

01/15/21 Berenberg
AstraZeneca price target lowered to 10,000 GBp from 10,500 GBp at Berenberg
01/15/21
Fly Intel: Top five analyst initiations
01/15/21 Deutsche Bank
AstraZeneca initiated with a Buy at Deutsche Bank
01/08/21 Raymond James
Alexion downgraded to Market Perform from Outperform at Raymond James
AZN AstraZeneca
$51.35 /

+0.05 (+0.10%)

AZN AstraZeneca
$51.35 /

+0.05 (+0.10%)

AZN AstraZeneca
$51.35 /

+0.05 (+0.10%)

AZN AstraZeneca
$51.35 /

+0.05 (+0.10%)

Hot Stocks
Quest enters agreement with CDC for genomic sequencing of Covid variants » 12:56
01/18/21
01/18
12:56
01/18/21
12:56
DGX

Quest Diagnostics

$124.35 /

-0.56 (-0.45%)

Quest Diagnostics…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
DGX Quest Diagnostics
$124.35 /

-0.56 (-0.45%)

DGX Quest Diagnostics
$124.35 /

-0.56 (-0.45%)

12/17/20 Morgan Stanley
Morgan Stanley cuts Quest Diagnostics to Equal Weight ahead of 2022 slowdown
12/17/20 Morgan Stanley
Quest Diagnostics downgraded to Equal Weight from Overweight at Morgan Stanley
10/26/20 Mizuho
Quest Diagnostics price target raised to $149 from $144 at Mizuho
10/21/20 Argus
Quest Diagnostics upgraded to Buy from Hold at Argus
DGX Quest Diagnostics
$124.35 /

-0.56 (-0.45%)

DGX Quest Diagnostics
$124.35 /

-0.56 (-0.45%)

DGX Quest Diagnostics
$124.35 /

-0.56 (-0.45%)

DGX Quest Diagnostics
$124.35 /

-0.56 (-0.45%)

Hot Stocks
Reliance Steel promotes Karla Lewis to President, names Arthur Ajemyan CFO » 12:46
01/18/21
01/18
12:46
01/18/21
12:46
RS

Reliance Steel

$127.66 /

-4.16 (-3.16%)

Reliance Steel &…

Reliance Steel & Aluminum announced that Karla Lewis has been promoted to President and appointed to the company's board. Prior to being named President, Lewis served as Senior Executive Vice President and Chief Financial Officer. In concert with Lewis' promotion, Reliance also announced the promotion of Arthur Ajemyan to Vice President, Chief Financial Officer effective January 15. Ajemyan became Vice President, Corporate Controller in May 2014.

ShowHide Related Items >><<
RS Reliance Steel
$127.66 /

-4.16 (-3.16%)

RS Reliance Steel
$127.66 /

-4.16 (-3.16%)

01/08/21 Deutsche Bank
Reliance Steel downgraded to Hold from Buy at Deutsche Bank
01/08/21 Deutsche Bank
Reliance Steel downgraded to Hold from Buy at Deutsche Bank
10/23/20
Fly Intel: Top five analyst upgrades
10/23/20 BofA
Reliance Steel upgraded to Buy from Neutral at BofA
RS Reliance Steel
$127.66 /

-4.16 (-3.16%)

Hot Stocks
Zomedica regained compliance with NYSE American's listing standards » 12:44
01/18/21
01/18
12:44
01/18/21
12:44
ZOM

Zomedica

$0.98 /

-0.0298 (-2.97%)

Zomedica said in a letter…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ZOM Zomedica
$0.98 /

-0.0298 (-2.97%)

ZOM Zomedica
$0.98 /

-0.0298 (-2.97%)

06/17/20 H.C. Wainwright
Zomedica price target lowered to 50c from 65c at H.C. Wainwright
  • 02
    Jul
Hot Stocks
Tronox 'very optimistic' about short-, long-term potential for TiO2 » 12:40
01/18/21
01/18
12:40
01/18/21
12:40
TROX

Tronox

$14.68 /

-0.375 (-2.49%)

The company said,…

The company said, "We remain confident that our vertical integration strategy will continue to provide a competitive advantage, allowing Tronox to deliver reliable, safe, quality, low-cost, sustainable tons to our customers while outperforming our TiO2 peers. The TiO2 business continues to benefit from the global industry recovery in 2021. With the current momentum, we are very optimistic about the short-, medium-, and long-term potential for both TiO2 and Tronox as the leading integrated supplier in the industry."

ShowHide Related Items >><<
TROX Tronox
$14.68 /

-0.375 (-2.49%)

TROX Tronox
$14.68 /

-0.375 (-2.49%)

12/28/20 Alembic Global
Dow Inc., Olin, Tronox named among 2021 chemical top picks at Alembic Global
06/05/20 JPMorgan
JPMorgan calls Tronox 'the forgotten cyclical'
05/08/20 Truist
Tronox price target lowered to $12 from $20 at SunTrust
TROX Tronox
$14.68 /

-0.375 (-2.49%)

Earnings
Tronox sees Q4 revenue $783M, consensus $696.29M » 12:39
01/18/21
01/18
12:39
01/18/21
12:39
TROX

Tronox

$14.68 /

-0.375 (-2.49%)

The company said,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
TROX Tronox
$14.68 /

-0.375 (-2.49%)

TROX Tronox
$14.68 /

-0.375 (-2.49%)

12/28/20 Alembic Global
Dow Inc., Olin, Tronox named among 2021 chemical top picks at Alembic Global
06/05/20 JPMorgan
JPMorgan calls Tronox 'the forgotten cyclical'
05/08/20 Truist
Tronox price target lowered to $12 from $20 at SunTrust
Hot Stocks
Tronox intends to increase annualized dividend to 32c from 28c » 12:38
01/18/21
01/18
12:38
01/18/21
12:38
TROX

Tronox

$14.68 /

-0.375 (-2.49%)

The company said,…

The company said, "The Board intends to increase our annualized dividend to $0.32 per share from $0.28 per share, which equates to a 14 percent increase effective with the regular first quarter 2021 dividend. This reflects the confidence we have in the trajectory of the recovery in the sector and in our differentiated business model and is consistent with our previously stated goal to increase dividends as business conditions permit."

ShowHide Related Items >><<
TROX Tronox
$14.68 /

-0.375 (-2.49%)

TROX Tronox
$14.68 /

-0.375 (-2.49%)

12/28/20 Alembic Global
Dow Inc., Olin, Tronox named among 2021 chemical top picks at Alembic Global
06/05/20 JPMorgan
JPMorgan calls Tronox 'the forgotten cyclical'
05/08/20 Truist
Tronox price target lowered to $12 from $20 at SunTrust
Hot Stocks
Tronox announces termination of TiZir Titanium and Iron acquisition agreement » 12:37
01/18/21
01/18
12:37
01/18/21
12:37
TROX

Tronox

$14.68 /

-0.375 (-2.49%)

Tronox Holdings released…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
TROX Tronox
$14.68 /

-0.375 (-2.49%)

TROX Tronox
$14.68 /

-0.375 (-2.49%)

12/28/20 Alembic Global
Dow Inc., Olin, Tronox named among 2021 chemical top picks at Alembic Global
06/05/20 JPMorgan
JPMorgan calls Tronox 'the forgotten cyclical'
05/08/20 Truist
Tronox price target lowered to $12 from $20 at SunTrust
Hot Stocks
Grifols to begin clinical trial in Spain for new COVID-19 drug » 12:34
01/18/21
01/18
12:34
01/18/21
12:34
GRFS

Grifols

$19.10 /

-0.05 (-0.26%)

Grifols announced it will…

Grifols announced it will begin a clinical trial in Spain to evaluate the safety and efficacy of a new COVID-19 drug based on the Grifols immunoglobulin Gamunex-C and containing anti-SARS-CoV-2 polyclonal antibodies from plasma donors who have recovered from the disease. "The new drug would provide immediate post-exposure protection against the virus and would be especially useful as a complement to the vaccine in the early phase after vaccination. In addition, it could protect the elderly and healthcare workers as well as immunocompromised patients for whom vaccination isn't recommended. It could also help contain outbreaks in places where the vaccination hasn't begun or is still underway," the company said. Grifols expects this clinical trial, led by the researchers Oriol Mitja and Bonaventura Clotet, from Germans Trias i Pujol Hospital in Barcelona, to begin in February 2021, with the possibility of results in the spring.

ShowHide Related Items >><<
GRFS Grifols
$19.10 /

-0.05 (-0.26%)

GRFS Grifols
$19.10 /

-0.05 (-0.26%)

01/13/21 Morgan Stanley
Grifols price target lowered to EUR 31 from EUR 32 at Morgan Stanley
12/09/20 Morgan Stanley
Grifols price target raised to EUR 32 from EUR 31 at Morgan Stanley
11/06/20 Morgan Stanley
Grifols price target raised to EUR 31 from EUR 30 at Morgan Stanley
10/30/20 Berenberg
Grifols price target lowered to EUR 24.50 from EUR 25.30 at Berenberg
GRFS Grifols
$19.10 /

-0.05 (-0.26%)

GRFS Grifols
$19.10 /

-0.05 (-0.26%)

Hot Stocks
New Oriental Education names CFO Zhihui Yang Executive President » 12:31
01/18/21
01/18
12:31
01/18/21
12:31
EDU

New Oriental Education

$172.75 /

-3.255 (-1.85%)

New Oriental Education…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
EDU New Oriental Education
$172.75 /

-3.255 (-1.85%)

01/05/21 Benchmark
GM, Roku, Marcus among Benchmark's Best Ideas for first half of 2021
12/28/20 Citi
Citi keeps 'long-term positive stance' on New Oriental Education
11/30/20 CLSA
New Oriental Education weakness a buying opportunity, says CLSA
11/25/20 Morgan Stanley
OneSmart downgraded to Equal Weight on margin pressure at Morgan Stanley
EDU New Oriental Education
$172.75 /

-3.255 (-1.85%)

EDU New Oriental Education
$172.75 /

-3.255 (-1.85%)

Hot Stocks
Partner says lawsuit against subsidiary recognized as class action » 12:30
01/18/21
01/18
12:30
01/18/21
12:30
PTNR

Partner Communications

$5.06 /

-0.1 (-1.94%)

Partner Communications…

Partner Communications announces that on January 15, 2021, the Lod-Central District Court ruled to recognize the lawsuit against a subsidiary of the company, 012 Smile Telecom, as a class action, which concerns the claim that 012 Smile sold to its customers data browsing packages at a specified speed, which is not possible for them to achieve since the infrastructure does not support this speed. A similar decision was also given in a lawsuit against a competing company. "The causes of action for which the motion was approved are, among others, misleading acts and breach of contract," the company said in a statement. 012 Smile is studying the decision and will treat it in accordance with the dates set by law, it added.

ShowHide Related Items >><<
PTNR Partner Communications
$5.06 /

-0.1 (-1.94%)

PTNR Partner Communications
$5.06 /

-0.1 (-1.94%)

12/02/20 Barclays
Partner Communications price target raised to ILS 1,900 at Barclays
Hot Stocks
Guardant Health announces partnership with Vall d'Hebron Institute of Oncology » 12:29
01/18/21
01/18
12:29
01/18/21
12:29
GH

Guardant Health

$159.27 /

+1.77 (+1.12%)

Guardant Health and Vall…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
GH Guardant Health
$159.27 /

+1.77 (+1.12%)

GH Guardant Health
$159.27 /

+1.77 (+1.12%)

01/14/21 Canaccord
Natera price target raised to $125 from $112 at Canaccord
01/12/21 Canaccord
Guardant Health price target raised to $170 from $145 at Canaccord
01/11/21
Fly Intel: Top five analyst initiations
01/11/21 Stifel
Guardant Health initiated with a Buy at Stifel
GH Guardant Health
$159.27 /

+1.77 (+1.12%)

  • 07
    Oct
  • 02
    Jun
GH Guardant Health
$159.27 /

+1.77 (+1.12%)

Hot Stocks
Calliditas says Phase 1 setanaxib trial shows favorable pharmacokinetic profile » 12:28
01/18/21
01/18
12:28
01/18/21
12:28
CALT

Calliditas Therapeutics

$30.55 /

-0.61 (-1.96%)

Genkyotex SA, a…

Genkyotex SA, a subsidiary of Calliditas Therapeutics, announced "positive Phase 1 data demonstrating a favorable safety and pharmacokinetic profile of high-dose setanaxib, Genkyotex's lead asset." The Phase 1 study demonstrated that setanaxib is well tolerated at the doses tested, with no safety signal or dose-limiting toxicity being identified, the company said. The results provide an opportunity for the company to pursue a pivotal Phase 2/3 clinical trial in patients with primary biliary cholangitis (PBC), based on interactions with the FDA, it added. The study assessed the safety and pharmacokinetics of oral setanaxib at selected doses in 46 healthy adult male and female subjects. The trial consisted of a single ascending dose part and a multiple ascending dose part with dosing up to 1600mg/day. Previously, doses of up to 800 mg/day were evaluated in a 24-week Phase 2 trial in PBC patients. In that trial, setanaxib dosed at 800 mg/day achieved reductions in markers of cholestasis, including alkaline phosphatase, and in multiple non-invasive markers of liver fibrogenesis, including liver stiffness and PRO-C3 and C3M. Significant improvement in fatigue was also achieved. All doses tested in that trial were well-tolerated, with no safety signal compared to placebo. Calliditas controls 86.2% of the share capital and total number of votes of Genkyotex.

ShowHide Related Items >><<
CALT Calliditas Therapeutics
$30.55 /

-0.61 (-1.96%)

CALT Calliditas Therapeutics
$30.55 /

-0.61 (-1.96%)

07/01/20 Citi
Calliditas Therapeutics initiated with a Buy at Citi
06/30/20 Jefferies
Calliditas Therapeutics initiated with a Buy at Jefferies
06/30/20 Stifel
Calliditas Therapeutics initiated with a Buy at Stifel
  • 05
    Jun
Hot Stocks
Celyad reports 10.6 months median overall survival in Phase 1 alloSHRINK trial » 12:25
01/18/21
01/18
12:25
01/18/21
12:25
CYAD

Celyad

$8.30 /

-0.02 (-0.24%)

Celyad Oncology announced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
CYAD Celyad
$8.30 /

-0.02 (-0.24%)

CYAD Celyad
$8.30 /

-0.02 (-0.24%)

12/08/20 H.C. Wainwright
Celyad price target lowered to $18 from $22 at H.C. Wainwright
03/26/20 Wells Fargo
Celyad price target lowered to $20 from $44 at Wells Fargo
03/25/20 H.C. Wainwright
Celyad price target lowered to $37 from $43 at H.C. Wainwright
Upgrade
Shoprite upgraded to Neutral from Sell at Goldman Sachs » 12:19
01/18/21
01/18
12:19
01/18/21
12:19
SRGHY

Shoprite

$0.00 /

+ (+0.00%)

Goldman Sachs analyst…

Goldman Sachs analyst Mikhail Butkov upgraded Shoprite to Neutral from Sell with a price target of ZAR 139, up from ZAR 126. The analyst cites valuation for the upgrade following the stock's underperformance. Butkov nos longer see downside to consensus estimates and now has a slightly more constructive view on the profitability recovery in broader Africa.

ShowHide Related Items >><<
SRGHY Shoprite
$0.00 /

+ (+0.00%)

09/02/20 HSBC
Shoprite upgraded to Buy from Hold at HSBC
General news
FX Summary: The dollar put in a firming session » 10:55
01/18/21
01/18
10:55
01/18/21
10:55

FX Summary: The dollar…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Downgrade
Klepierre downgraded to Underperform from Neutral at BofA » 09:43
01/18/21
01/18
09:43
01/18/21
09:43
KLPEF

Klepierre

$0.00 /

+ (+0.00%)

BofA analyst Marc Mozzi…

BofA analyst Marc Mozzi downgraded Klepierre to Underperform from Neutral. The analyst is "cautiously optimistic" about the outlook for European real estate in 2021.

ShowHide Related Items >><<
KLPEF Klepierre
$0.00 /

+ (+0.00%)

01/15/21 JPMorgan
Klepierre price target lowered to EUR 20 from EUR 22 at JPMorgan
12/10/20 Goldman Sachs
Klepierre upgraded to Neutral from Sell at Goldman Sachs
11/20/20 RBC Capital
Klepierre price target raised to EUR 25 from EUR 23 at RBC Capital
11/09/20 HSBC
Klepierre upgraded to Buy from Hold at HSBC
Upgrade
Great Portland Estates upgraded to Neutral from Underperform at BofA » 09:43
01/18/21
01/18
09:43
01/18/21
09:43
GPEAF

Great Portland Estates

$0.00 /

+ (+0.00%)

BofA analyst Marc Mozzi…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
GPEAF Great Portland Estates
$0.00 /

+ (+0.00%)

01/05/21 Morgan Stanley
Great Portland Estates downgraded to Equal Weight from Overweight at Morgan Stanley
10/20/20 BofA
Great Portland Estates downgraded to Underperform from Neutral at BofA
06/25/20 HSBC
Great Portland Estates upgraded to Hold from Reduce at HSBC
06/04/20 Barclays
Great Portland Estates price target lowered to 570 GBp from 740 GBp at Barclays
Upgrade
Shurgard Self Storage upgraded to Buy from Neutral at BofA » 09:42
01/18/21
01/18
09:42
01/18/21
09:42
SSSAF

Shurgard Self Storage

$0.00 /

+ (+0.00%)

BofA analyst Marc Mozzi…

BofA analyst Marc Mozzi upgraded Shurgard Self Storage to Buy from Neutral. The analyst is "cautiously optimistic" about the outlook for European real estate in 2021.

ShowHide Related Items >><<
SSSAF Shurgard Self Storage
$0.00 /

+ (+0.00%)

11/04/20 JPMorgan
Shurgard Self Storage upgraded to Overweight from Neutral at JPMorgan
09/03/20 Stifel
Shurgard Self Storage initiated with a Hold at Stifel
07/30/20 JPMorgan
Shurgard Self Storage price target lowered to EUR 27 from EUR 32 at JPMorgan
Upgrade
Gecina upgraded to Buy from Neutral at BofA » 09:42
01/18/21
01/18
09:42
01/18/21
09:42
GECFF

Gecina

$0.00 /

+ (+0.00%)

BofA analyst Marc Mozzi…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
GECFF Gecina
$0.00 /

+ (+0.00%)

01/05/21 Morgan Stanley
Gecina price target raised to EUR 130 from EUR 120 at Morgan Stanley
09/11/20 HSBC
Gecina upgraded to Buy from Hold at HSBC
09/03/20 Morgan Stanley
Gecina price target lowered to EUR 120 from EUR 125 at Morgan Stanley
07/28/20 Barclays
Gecina price target raised to EUR 131 from EUR 130 at Barclays

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.